CSPC TRACE 2 Study Listed in 2023 Top Ten Stroke Star Studies

An article authored by Wang Yongjun, Xiong Yunyun, and Li Guangshuo was recently published in the Chinese Journal of Stroke, which gives a comprehensive review of international stroke studies conducted in 2023 and lists the 2023 Top Ten Stroke Star Studies. The TRACE 2 study sponsored by CSPC was listed as a Chinese star among global stroke studies.

The article indicates that investigators in the cerebrovascular field worldwide contributed a sea of quality clinical studies in 2023. These studies not only demonstrate scientific and sophisticated study designs but, more importantly, provide new answers and ideas for key clinical issues. The investigators added multiple new interventions in 2023, ranging from emergency intervention in the acute stage of stroke, and in-hospital management, to secondary prevention and long-term management. Encouragingly, the emergence of increasing quality studies from China in 2023 reveals that Chinese power has become important in international clinical studies on stroke.

Sponsored by CSPC and led by Professor Wang Yongjun from Beijing Tiantan Hospital, Capital Medical University, the TRACE 2 study on Mingfule (Recombinant Human TNK Tissue-type Plasminogen Activator for Injection, rhTNK-tPA, a CSPC's innovative drug) was listed in the article. The article points out that the publication of the TRACE 2 study in the Lancet marks the first appearance of the registered clinical trial of a cerebrovascular drug with China's independent intellectual property rights in a top international medical journal. In the article, TNK has become a new star for thrombolysis, and the evidence for the efficacy of China's TNK in thrombolysis has rewritten the relevant UK guideline (2023 edition of the National Clinical Guideline for Stroke for the UK and Ireland).